Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$14.81
+0.16 (+1.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $138.3M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
11.1x
↓EV/EBITDA
5.7x
↓ROE
9.0%
↑Gross Margin
55.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.7%
FCF CAGR
-10.2%
FCF margin
15.1%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.39B · net income $416.3M · FCF $210.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.39B | $1.39B | $1.34B | $1.15B | $1.15B |
| Net Income | $416.3M | $416.3M | $184.5M | $361.8M | $93.6M |
| EBITDA | $537.3M | $537.3M | $299.8M | $488.3M | $185.4M |
| EPS | 1.35 | 1.35 | 0.60 | 1.17 | 0.30 |
| Gross Margin | 55.3% | 55.3% | 55.1% | 59.4% | 57.6% |
| Operating Margin | 8.1% | 8.1% | 6.7% | 11.4% | 7.3% |
| Net Margin | 29.9% | 29.9% | 13.8% | 31.4% | 8.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 4.52 | 4.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $210.0M | $210.0M | $34.5M | $138.3M | $290.5M |
| Returns | |||||
| ROE | 9.0% | 9.0% | 3.9% | 7.4% | 2.2% |
| Valuation | |||||
| P/E | 11.05 | 11.05 | 25.08 | 13.54 | 42.67 |
| EV/EBITDA | 5.72 | 5.72 | 10.14 | 6.03 | 12.12 |
| P/B | 0.99 | 0.99 | 0.97 | 1.00 | 0.92 |
| Growth & Yield | |||||
| Revenue Growth | 4.2% | 4.2% | 15.9% | 0.6% | — |
| EPS Growth | 125.0% | 125.0% | -48.6% | 284.3% | — |
| Dividend Yield | 7.6% | 7.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-0.9%
EPS terminal req.
$1.31
Spread vs growth
125.9%
5Y implied EPS CAGR
3.3%
EPS terminal req.
$1.59
Spread vs growth
121.7%
10Y implied EPS CAGR
6.6%
EPS terminal req.
$2.56
Spread vs growth
118.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.6%
Start / end P/E
23.6x → 11.1x
EPS bridge
0.60 → 1.35
Residual
-66.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.